ChemoCentryx Newswire (Page 2)

ChemoCentryx Newswire (Page 2)

Comprehensive Real-Time News Feed for ChemoCentryx. (Page 2)

Results 21 - 40 of 479 in ChemoCentryx

  1. ChemoCentryx, Inc. (CCXI) Downgraded by BidaskClubRead the original story w/Photo

    Aug 19, 2017 | AmericanBankingNews.com

    CCXI has been the subject of several other reports. Cowen and Company reaffirmed a "hold" rating on shares of ChemoCentryx in a research note on Tuesday, August 8th.

    Comment?

  2. ChemoCentryx, Inc. (CCXI) Earns "Hold" Rating from Cowen and CompanyRead the original story w/Photo

    Aug 18, 2017 | IntersportsWire

    's stock had its "hold" rating restated by research analysts at Cowen and Company in a research report issued to clients and investors on Tuesday, August 8th. Separately, Zacks Investment Research upgraded shares of ChemoCentryx from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research note on Monday, July 17th.

    Comment?

  3. ChemoCentryx, Inc. (CCXI) Insider Sells $293,400.00 in StockRead the original story w/Photo

    Aug 18, 2017 | IntersportsWire

    ChemoCentryx, Inc. insider Petrus Bekker sold 30,000 shares of the company's stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $9.78, for a total value of $293,400.00.

    Comment?

  4. ChemoCentryx, Inc. (CCXI) Stock Rating Upgraded by Zacks Investment ResearchRead the original story w/Photo

    Aug 18, 2017 | Daily Political

    According to Zacks, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

    Comment?

  5. Critical Contrast: Tokai PharmaceuticalsRead the original story w/Photo

    Aug 17, 2017 | AmericanBankingNews.com

    Tokai Pharmaceuticals and ChemoCentryx are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Tokai Pharmaceuticals presently has a consensus price target of $1.15, suggesting a potential downside of 69.41%.

    Comment?

  6. ChemoCentryx, Inc. (NASDAQ:CCXI) Sets New 12-Month High at $10.69Read the original story w/Photo

    Aug 14, 2017 | IntersportsWire

    ChemoCentryx, Inc. shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $10.69 and last traded at $10.69, with a volume of 514,661 shares trading hands.

    Comment?

  7. ChemoCentryx, Inc. (NASDAQ:CCXI) Cut to "Buy" at BidaskClubRead the original story w/Photo

    Aug 13, 2017 | IntersportsWire

    Several other research analysts have also commented on CCXI. Cowen and Company restated a "hold" rating on shares of ChemoCentryx in a research note on Tuesday, August 8th.

    Comment?

  8. ChemoCentryx (CCXI) Earning Somewhat Negative Media Coverage, Analysis FindsRead the original story w/Photo

    Aug 13, 2017 | Daily Political

    Media coverage about ChemoCentryx has been trending somewhat negative recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time.

    Comment?

  9. ChemoCentryx, Inc. (CCXI) Lowered to Sell at Zacks Investment ResearchRead the original story w/Photo

    Aug 13, 2017 | The Breeze

    According to Zacks, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

    Comment?

  10. First Quadrant L P Ca Takes Position in ChemoCentryx, Inc.Read the original story w/Photo

    Aug 12, 2017 | IntersportsWire

    First Quadrant L P CA bought a new stake in shares of ChemoCentryx, Inc. during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 23,349 shares of the biopharmaceutical company's stock, valued at approximately $219,000.

    Comment?

  11. ChemoCentryx, Inc. (CCXI) Downgraded by Zacks Investment Research to SellRead the original story w/Photo

    Aug 12, 2017 | IntersportsWire

    According to Zacks, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

    Comment?

  12. ChemoCentryx, Inc. (NASDAQ:CCXI) Raised to "Buy" at Zacks Investment ResearchRead the original story w/Photo

    Aug 11, 2017 | IntersportsWire

    The firm currently has $12.00 price objective on the biopharmaceutical company's stock. According to Zacks, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

    Comment?

  13. ChemoCentryx's (CCXI) CEO Thomas Schall on Q2 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Aug 8, 2017 | Seeking Alpha

    ... Steve Klass of Burns McClellan. Mr. Klass, please go ahead. Thanks, Britney. Good afternoon, and welcome to the ChemoCentryx Second Quarter 2017 Financial Results Conference Call. This afternoon, the company issued a press release providing an ...

    Comment?

  14. ChemoCentryx, Inc. (NASDAQ:CCXI) Downgraded to Buy at BidaskClubRead the original story w/Photo

    Aug 10, 2017 | Daily Political

    A number of other research analysts have also weighed in on the stock. Zacks Investment Research raised shares of ChemoCentryx from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a research note on Monday, July 17th.

    Comment?

  15. Autoimmune Drugs Market 2016 Size, Analysis, Trend and OverviewRead the original story

    Aug 10, 2017 | Emailwire.com

    ... - Astellas Pharma - AstraZeneca - Baxter - Boehringer Ingelheim - Can-Fite BioPharma - Celgene - Celltrion - ChemoCentryx - Coherus BioSciences - Daiichi Sankyo - Eisai - Eli Lilly - Gilead Sciences - GSK - Hospira - Idera Pharmaceuticals - ...

    Comment?

  16. ChemoCentryx Reports Second Quarter 2017 Financial Results And Recent HighlightsRead the original story

    Aug 8, 2017 | BioSpace

    MOUNTAIN VIEW, Calif., Aug. 08, 2017 -- ChemoCentryx, Inc., , a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced financial results for the second quarter ended June 30, 2017. "We've had a highly productive second quarter, activating many new sites in our avacopan Phase III ADVOCATE trial, which is producing a multiplier effect on patient enrollment," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.

    Comment?

  17. ChemoCentryx, Inc. (NASDAQ:CCXI) Insider Petrus Bekker Sells 30,000 SharesRead the original story w/Photo

    Aug 9, 2017 | IntersportsWire

    ChemoCentryx, Inc. insider Petrus Bekker sold 30,000 shares of the business's stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $9.78, for a total value of $293,400.00.

    Comment?

  18. Petrus Bekker Sells 76,013 Shares of ChemoCentryx, Inc. (CCXI) StockRead the original story w/Photo

    Aug 8, 2017 | IntersportsWire

    ChemoCentryx, Inc. insider Petrus Bekker sold 76,013 shares of the company's stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $9.95, for a total value of $756,329.35.

    Comment?

  19. ChemoCentryx, Inc. (CCXI) Receives Hold Rating from Cowen and CompanyRead the original story w/Photo

    Aug 8, 2017 | IntersportsWire

    's stock had its "hold" rating reaffirmed by analysts at Cowen and Company in a research report issued on Tuesday. Separately, Zacks Investment Research raised ChemoCentryx from a "hold" rating to a "buy" rating and set a $12.00 price target for the company in a research note on Monday, July 17th.

    Comment?

  20. Insider Selling: ChemoCentryx, Inc. (NASDAQ:CCXI) Director Sells 2,250 Shares of StockRead the original story w/Photo

    Aug 4, 2017 | Daily Political

    ChemoCentryx, Inc. Director Roger C. Lucas sold 2,250 shares of the business's stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $10.07, for a total value of $22,657.50.

    Comment?